IRIS
CLERICO, ALDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 54.728
EU - Europa 36.203
AS - Asia 21.277
SA - Sud America 3.537
AF - Africa 407
Continente sconosciuto - Info sul continente non disponibili 203
OC - Oceania 32
Totale 116.387
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 53.299
GB - Regno Unito 14.487
SG - Singapore 7.810
RU - Federazione Russa 6.676
CN - Cina 6.056
UA - Ucraina 3.967
IT - Italia 3.861
VN - Vietnam 3.120
BR - Brasile 2.828
DE - Germania 2.432
HK - Hong Kong 1.927
CA - Canada 1.052
SE - Svezia 958
FI - Finlandia 933
FR - Francia 867
DK - Danimarca 784
PL - Polonia 641
BD - Bangladesh 534
IN - India 371
IL - Israele 272
AR - Argentina 244
IE - Irlanda 203
MX - Messico 203
EU - Europa 202
ZA - Sudafrica 154
TR - Turchia 150
IQ - Iraq 145
ID - Indonesia 141
EC - Ecuador 110
JP - Giappone 98
VE - Venezuela 94
CO - Colombia 91
PK - Pakistan 89
NL - Olanda 87
ES - Italia 69
SA - Arabia Saudita 67
CL - Cile 64
KR - Corea 61
UZ - Uzbekistan 61
MA - Marocco 56
MY - Malesia 52
PH - Filippine 44
RO - Romania 39
AE - Emirati Arabi Uniti 35
PY - Paraguay 35
JM - Giamaica 34
JO - Giordania 34
TN - Tunisia 34
KE - Kenya 33
LT - Lituania 33
UY - Uruguay 32
EG - Egitto 30
NP - Nepal 29
AT - Austria 25
DZ - Algeria 25
AU - Australia 22
ET - Etiopia 21
TT - Trinidad e Tobago 21
HN - Honduras 19
PE - Perù 19
AZ - Azerbaigian 18
NI - Nicaragua 18
SK - Slovacchia (Repubblica Slovacca) 18
CR - Costa Rica 17
IR - Iran 15
PA - Panama 15
TH - Thailandia 15
KZ - Kazakistan 14
BO - Bolivia 13
OM - Oman 13
PT - Portogallo 13
RS - Serbia 13
BH - Bahrain 12
TW - Taiwan 12
AL - Albania 11
CH - Svizzera 11
DO - Repubblica Dominicana 11
PS - Palestinian Territory 11
BE - Belgio 9
BY - Bielorussia 9
CZ - Repubblica Ceca 9
LB - Libano 9
PR - Porto Rico 9
SV - El Salvador 9
CI - Costa d'Avorio 8
GT - Guatemala 8
KW - Kuwait 8
NG - Nigeria 8
NZ - Nuova Zelanda 8
QA - Qatar 8
AM - Armenia 7
AO - Angola 7
BB - Barbados 7
BG - Bulgaria 7
HR - Croazia 7
SN - Senegal 7
KH - Cambogia 6
BA - Bosnia-Erzegovina 5
HU - Ungheria 5
KG - Kirghizistan 5
Totale 116.295
Salva come PNG Salva come JPEG
Città #
Southend 12.638
Dallas 8.312
Woodbridge 5.122
Ann Arbor 4.000
Singapore 3.506
Chandler 3.260
Houston 3.017
San Jose 2.761
San Mateo 2.512
Beijing 2.391
Ashburn 2.260
Dearborn 1.956
Jacksonville 1.928
Hong Kong 1.826
Falls Church 1.474
Moscow 1.402
Fairfield 1.187
The Dalles 1.151
Seattle 1.065
Cambridge 949
Wilmington 840
Dong Ket 828
Milan 808
Stevenage 762
Portsmouth 694
Hefei 689
Boardman 664
Warsaw 623
Lawrence 611
Ho Chi Minh City 563
Lauterbourg 560
Los Angeles 536
Brooklyn 526
Pisa 471
Rome 469
Ottawa 461
Chicago 425
Hanoi 399
Santa Clara 339
New York 298
Helsinki 297
São Paulo 272
Buffalo 269
Tel Aviv 249
Council Bluffs 245
Montréal 195
Dublin 189
Old Bridge 185
Salt Lake City 176
San Diego 139
Figino 118
Beauharnois 107
Mexico City 104
Redwood City 101
Rio de Janeiro 101
Munich 99
Montreal 96
Norwalk 95
Orem 93
London 88
Tampa 88
Johannesburg 86
Da Nang 85
Tokyo 84
Chennai 83
Elk Grove Village 73
Stockholm 68
Phoenix 65
Haiphong 64
Belo Horizonte 61
Atlanta 59
Denver 59
Tashkent 54
Toronto 53
Turin 52
Baghdad 51
Brasília 51
San Francisco 51
Dhaka 50
Frankfurt am Main 50
Boston 49
Curitiba 49
Naples 47
Bologna 45
Porto Alegre 45
Guangzhou 44
Hải Dương 42
Amsterdam 40
Florence 40
Fremont 40
Augusta 39
Poplar 39
Istanbul 38
Washington 38
Columbus 37
Kansas City 37
Manchester 37
Biên Hòa 36
Quito 36
Nuremberg 35
Totale 79.601
Salva come PNG Salva come JPEG
Nome #
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.706
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 697
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 489
siRNA-mediated targeting of endothelial VWF prevents ET-1 upregulation in porcine aortic endothelial cells chronically exposed to angiotensin II 459
Downregulation of von Willebrand Factor prevents Ang II-induced endothelin-1 expression independently of eNOS activation in porcine endothelial cells 442
Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. 407
Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides 371
A chemiluminescence immunoassay for CA 15-3, CA 125, CA 19-9: evaluation using quality control sera assayed in an interlaboratory survey 342
Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. 332
Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform 332
State of the art of BNP and NT-proBNP immunoassays: The CardioOrmoCheck study 330
Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients with Stable Angina 330
Abnormal circulating levels of muscle enzymes and myoglobin in hypothyroidism: their significance and usefulness in follow-up of replacement therapy of the metabolic disorder 329
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 326
Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin i 325
125I-Endothelin-1 binding sites in human cardiac tissue 323
The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. 315
A chromatographic method for the determination of uric acid turnover in man 312
A new immunoradiometric assay for the measurement of N-terminal fragment of proatrial natriuretic peptide in human plasma: relationship with atrial and brain natriuretic peptides 307
N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives 305
A sensitive and accurate plasma noradrenaline assay using a modified fluorimetric method. 303
Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnI+3 for the measurement of cardiac troponin I using both patients and quality control plasma samples 302
A ligand-receptor binding assay of urinary and circulating endogenous digitalis-like factors 294
Valutazione delle caratteristiche analitiche di un nuovo metodo di dosaggio del BNP 293
Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. 291
Inibizione dell'asse ipofiso-gonadale dopo trattamento con un farmaco anabolizzante (Metandrostenolone, Dianabol) 290
Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia 290
Acute effects of intravenous amiodarone administration on thyroid function in arrhthmic patients 290
A simplified method of measuring free triiodothyronine in serum by conbined equilibrium dialysis and gel Sephadex extraction 289
A chromatographic method for the determination of uric acid turnover in man 289
Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system. 288
Cardiac biomarker testing in the clinical laboratory:Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. 285
Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review 283
Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: New challenges and perspectives 282
Direct comparison of B-Type Natriuretic Peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data 276
Evaluation of analytical performance and qualità specifications of a novel immunoenzymometric assay for cTnI: comparison with cTnI and cTnT immunoassays 276
Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure 276
A false positive case of cardiac troponin I: Which diagnostic approach? 275
Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia 273
Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure 269
Marcatori di rimodellamento e fibrosi cardiaca 269
Evaluation of reference change values for a hs-cTnI immunoassay using both plasma samples of healthy subjects and patients and quality control samples 269
A new chemiluminescence immunoassay for CA 15-3, CA 125, CA 19-9: evaluation using QC sera assayed in an interlaboratory survey 268
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 267
Acute effects of intravenous amiodarone on sulphate metabolites of thyroid hormones in arrhythmic patients 265
A simple, sensitive and rapid radioimmunoassay for measurement of urinary albumin 265
Acute effects of intravenous amiodarone administration on thyroid function in arrhthmic patients 264
Acute effects of intravenous amiodarone on sulphate metabolite of thyroid hormones in arrhythmic patients 264
B-type natriuretic peptide secretion following scuba diving 261
A rapid procedure for the quantization of natriuretic peptide RNAs by competitive RT-PCR in congenital heart defects 260
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 260
ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure 259
Valutazione esterna di qualità dei peptidi natriuretici BNP e NT-proBNP: risultati del programma Cardioormocheck 255
N-terminal proB-type natriuretic peptide (NT-proBNP) is superior to BNP for the detection of eraly/mild forms of heart failure 254
Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones 252
Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice 252
Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. 249
Criteri per la valutazione delle caratteristiche analitiche e della utilità clinica dei nuovi biomarcatori cardiaci 249
Methodological assessment of mitochondrial respiratory chain-enzyme activities in cardiac tissue 248
Forme molecolari della gamma-glutammiltransferasi: caratteristiche e biogenesis. 248
Stato dell’arte dell’immunodosaggio dei peptidi natriuretici di tipo B 248
Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival 248
Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance 247
Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. 244
Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations 244
The 99th percentile of reference population for cTnI and cTnT assay: Methodology, pathophysiology and clinical implications 244
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences 243
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. 242
Natriuretic peptide testing in primary care patients. 242
The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex 242
N-terminal fragment of brain natriuretic peptide predicts vascular health and subclinical atherosclerosis: results from MEHLP study 242
Rilevanza clinica e interpretazione dei marcatori biochimici nello scompenso cardiaco 240
Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform 240
Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review 239
The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery 237
Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method 237
State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). 236
Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin i 235
No variation in Hsp70 mRNA level during cardiac surgery in pediatric patients evaluated by semiquantitative RT-PCR 234
S-nitrosoglutathione as a substrate of gamma-glutamyltransferase (GGT)- A kinetic study 234
Evaluation and Comparison with Other High-Sensitivity Methods of Analytical Performance and Measured Values of a New Laboratory Test for Cardiac Troponin I Assay 233
Prognostic value of combined use of B-ype natriuretic peptides and interleukine-6 in predicting cardiac mortalità in end-stage renal disease patients 233
Proposta per l’utilizzo in Pronto Soccorso delle troponine cardiache misurate con metodi di ultima generazione in pazienti con sospetto di sindrome coronarica acuta senza sopraslivellamento del tratto ST 233
C-type natriuretic peptide expression in patients with chronic heart failure: effects of aerobic training. 231
Cardiac troponins as biomarkers for cardiac disease 230
BNP values in the first days of life measured with an automated immunoassay platform 228
New biomarkers for risk stratifications in patients with heart failure: high-sensitivity troponin I and galectin-3 228
Diagnosis of preclinical /mild heart failure with B-type natriuretic peptides: compariosn betwwen BNP and NT-proBNP immunoassay methods 227
Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty 226
Prognostic complexity of heart failure and network analysis: the holistic risk stratification 226
Cheyne-Stokes respiration is associated with neurohormonal activation in patients with heart failure 226
Comparison of two BNP immunoassays using the same antibodies and standard materials 226
Plasma gamma-glutamyltransferase fractions: diagnostic and prognostic predictive value 226
Genomic medicine and thrombotic risk: who, when, how and why? 225
New and emerging biomarkers of heart failure 224
Detection of mtDNA with 4977 bp deletion in blood cells and atherosclerotic lesions of patients with coronary artery disease. 224
Comparison of the diagnostic accuracy of BNP and NT-proBNP in acute and chronic heart failure. Reply Letter 223
Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients 221
Gamma-glumamyl-transferase levels are associated with inflammatory activation, myocardial dysfunction and mortality in pateints with ST-elevation myocardial infarction 221
Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects. 220
Totale 29.020
Salva come PNG Salva come JPEG
Categoria #
all - tutte 563.550
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 563.550
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228.252 276 1.896 208 966 62 55 887 1.779 511 924 56 632
2022/20236.603 616 117 70 1.176 1.151 1.248 12 531 1.101 143 267 171
2023/20241.761 370 85 290 104 72 276 232 72 25 47 29 159
2024/202516.831 116 65 1.084 346 275 1.163 2.348 5.046 1.570 1.069 2.463 1.286
2025/202636.457 1.629 7.932 3.339 3.207 3.369 2.012 6.125 1.660 1.684 2.521 940 2.039
2026/2027325 325 0 0 0 0 0 0 0 0 0 0 0
Totale 116.612